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Abstract
Background – Markers of pancreatic cancer invasion were investigated in two clonal
populations of the cell line, MiaPaCa-2, Clone #3 (high invasion) and Clone #8 (low invasion)
using proteomic profiling of an in vitro model of pancreatic cancer.
Materials and methods – Using 2D-DIGE followed by MALDI-TOF MS, two clonal sub-
populations of the pancreatic cancer cell line, MiaPaCa-2 with high and low invasive capacities
were incubated on matrigel 24 hours prior to analysis to stimulate cell-ECM contact and mimic in
vivo interaction with the basement membrane.
Results - Sixty proteins were identified as being differentially expressed (>1.2 fold change and p
≤ 0.05) between Clone #3 and Clone #8. Proteins found to have higher abundance levels in the
highly invasive Clone #3 compared to the low invasive Clone #8 include members of the
chaperone activity proteins and cytoskeleton constituents whereas metabolism-associated and
catalytic proteins had lower abundance levels. Differential protein expression levels of
ALDH1A1, VIM, STIP1 and KRT18 and GAPDH were confirmed by immunoblot. Using RNAi
technology, STIP1 knockdown significantly reduced invasion and proliferation of the highly
invasive Clone #3. Knockdown of another target, VIM by siRNA in Clone #3 cells also resulted
in decreased invasion abilities of Clone #3. Elevated expression of STIP1 was observed in
pancreatic tumour tissue compared to normal pancreas, whereas ALDH1A1 stained at lower
levels in pancreatic tumours, as detected by immunohistochemistry.
Conclusion - Identification of targets which play a role in the highly invasive phenotype of
pancreatic cancer may help to understand the biological behaviour, the rapid progression of this
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cancer and may be of importance in the development of new therapeutic strategies for pancreatic
cancer.
Background
Pancreatic cancer is the tenth most common cancer in Europe, and accounts for approximately
2.5% of cancer in males and females [1]. The median survival is 8-12 months for patients
presenting with locally advanced and unresectable disease, and only 3-6 months for those with
metastatic disease at presentation [2]. Surgery offers the best curative treatment, but, <15% of
patients present with tumours eligible for resection at initial diagnosis due to aggressive local and
perineural invasion, early metastasis to liver and lymph nodes, formation of desmoplastic stromal
reaction within the tumour and resistance to chemotherapy and radiation [3]. Therefore, there is
an urgent need to develop molecular diagnostic biomarkers and targets to detect pancreatic cancer
at an earlier stage, which may help to improve treatment and survival of pancreatic cancer
patients. The development of invasive and metastatic pancreatic cancer is complex and poorly
understood. Metastasis is defined as the ability of tumour cells at the primary site to invade local
tissue, cross the basement membrane and tissue barriers and re-establish at distant secondary
locations. This process of metastasis is not random. A cascade of complex interactions between
the cancer cell and its surroundings results in the metastatic cascade; Tumour cells must first
break signalling contact with neighbouring cells, degrade and penetrate the basement membrane
and then invade the interstitial stroma in order to reach blood/lymph vessels [4]. Intravasation
requires penetration of the blood/lymph systems. The tumour cells must then exit the lymph
system or blood stream at a new site (extravasation) and proliferate in the secondary organ [5].
The heterogeneous nature of some tumours is associated with sub-populations of highly
metastatic tumour cells existing at very early stages of primary tumour development [6]. We
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previously isolated clonal sub-populations of the human pancreatic cancer cell line, MiaPaCa-2
through serial dilution. Two of these sub-clones, Clone #3 and Clone #8 displayed altered
malignant properties. Clone #3 showed higher invasion with low levels of adhesion, while Clone
#8 displayed decreased invasion with increased adhesion to ECM proteins. Clone #8 was
sensitive to anoikis, and displayed low colony-forming efficiency in an anchorage-independent
growth assay compared to Clone #3. This model provides a unique in vitro representation of an
invasive pancreatic carcinoma. The aim of this study was to identify novel proteins involved in
pancreatic cancer invasion using an in vitro model of pancreatic cancer invasion. Protein
expression of Clone #3 (highly invasive) and Clone #8 (low level of invasion) were compared
using 2D-DIGE followed by MALDI-TOF-MS for protein profiling.
Results
Invasion assays
Two clonal populations, Clone #3 and Clone #8 were isolated from the human pancreatic cancer
cell line, MiaPaCa-2. Clone #3 is highly invasive compared to the parent, MiaPaCa-2 whilst
Clone #8 displays distinctively less invasion than the parent as shown by the total number of cells
invading after preincubation on matrigel for 24 hrs (Fig 1).
Identification of proteins by DIGE analysis
To investigate proteins potentially involved in invasion in this model for human pancreatic
cancer, we systematically analysed protein expression from Clone #3 and Clone #8 grown on
matrigel 24 hours prior to protein extraction, using 2D-DIGE. Biological variation analysis of
spots showing greater than 1.2-fold change in expression with a t-test score of less than 0.05,
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revealed 60 differentially expressed proteins between Clone #3 and Clone #8 (Figure 2 and Table
1S Additional file 1). Table 1S is a list of the differentially expressed proteins with their protein
accession numbers, % coverage, theoretical pI, and molecular weight, calculated fold change, P
values and function-(Human Protein Reference Database (HPRD)) (http://www.hprd.org).
Theoretical pI and MW provides information not only on full-length protein expression, but
expression of modified, splice variant, cleavage product, and processed proteins. Any protein
modification that leads to a change in overall protein charge and/or molecular weight (MW) will
generate a different spot on the 2D gel. Modification specific staining can identify whether a
specific post-translational modification is responsible for the shift, and mass spectrometry can
potentially identify the source of isoelectric point (pI) and/or MW differences.
Of the 60 proteins identified, 49 of these proteins were found in higher abundance and 11 were
expressed at lower levels in the highly invasive Clone #3. Many highly expressed proteins in
Clone #3 correspond to the cytoskeleton (vimentin, vinculin, tubulin alpha-6, beta-tubulin, alpha-
tubulin and gamma-actin), the chaperone family of proteins (heat shock proteins, KIAA0098,
stress-induced phosphoprotein 1 and MTHSP75). Other highly abundant proteins included some
associated with translation and transport, receptor signalling and ligase activity. Among the 11
low abundant proteins, most are involved in the catalytic/glycolysis activity. Keratin 18 (KRT18),
a cytoskeletal protein is 2.9-fold less abundant in Clone #3 cells, and low expression of KRT18
has been previously implicated in a more aggressive phenotype [7].
Gene ontology enrichment analysis
Using DAVID gene ID tool software (http://david.abcc.ncifcrf.gov), all the proteins differentially
expressed in our model were converted to their gene IDs. Gene ontology (GO STAT)
(http://gostat.wehi.edu.au/cgi-bin/goStat.pl) was then used to classify the proteins and their
 6
corresponding genes into gene categories and assign functional categories. Enrichment of a
particular ontology term, for significantly expressed genes in response to the process under study,
means that the ontology term is likely to be involved in the process. In our study, the process
refers to invasion in pancreatic cancer. Using the over-expression function of the software and
false discovery rate (Benjamini) stats, 52 GO terms were found significantly enriched between
Clone #3 versus Clone #8. The molecular functions of the proteins identified in this study were
classified according to GO database. Figure 3 displays the top 10 GO biological process
categories of invasion-related differentially expressed proteins in our pancreatic cancer model.
Profiles based on differentially expressed proteins showed clear differences between the two cell
lines. For example, the “cytoplasm” term achieved the highest degree of significance in the up-
regulated gene class (p = 1.40E-09), with “glycolysis” (p = 4.05E-07) and “nucleotide binding”
(p = 1.04E-06) also highly significant terms. In the down-regulated class, “oxidoreductase
activity” (p = 0.0006), “aldehyde dehydrogenase activity” (p = 0.003) and “mitochondrion” (p =
0.03) were also significantly enhanced.
Confirmation of identified proteins by immunoblot analysis
Immunoblot analysis was carried out to confirm the differential expression observed for A.
ALDH1A1, B. VIM, C. STIP1, D. KRT18 and E. GAPDH in Clone #3 and Clone #8. In all
cases, the results were consistent with proteomic analysis. Figure 4 (A-E) details the high and low
abundance of proteins by (i) 3D spot image, (ii) protein expression map and (iii) immunoblot in
the comparison of Clone #3 versus Clone #8.
A novel role for stress-induced phosphoprotein 1 (STIP1) in invasion
STIP1 expression levels were 2-fold higher in Clone #3 compared to Clone #8. Invasion assays
were carried out on untreated Clone #3 cells, cells treated with scrambled siRNA and three
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independent siRNAs for STIP1 (Fig 5 A and B). STIP1 siRNA transfection significantly reduced
the invasion of Clone #3 cells (3-fold (p=0.0002) with STIP1- siRNA (1), 2-fold (p=0.0002) with
STIP1- siRNA (2) and 2-fold (p=0.0003) with STIP1- siRNA (3). STIP1 had no effect on
adhesion (data not shown), however, transfection of Clone #3 cells with STIP1-siRNAs
decreased proliferation by 13% (p=0.04) with STIP1- siRNA (1) and 27% (p=0.003) with STIP1-
siRNA (2). STIP1- siRNA (3) did not alter the proliferation of the cells (Fig 5 C).
Vimentin (VIM) involvement in the invasion of pancreatic cancer cells
VIM was detected at 5.5-fold higher levels in Clone #3 compared to Clone #8. Transfection of
VIM-siRNAs reduced the expression of VIM in Clone #3 cells (Fig 6 A). Invasion of VIM-
siRNA transfected Clone #3 cells reduced invasion 4-fold (p=0.00036) with VIM-siRNA (1), 6-
fold (p=0.00031) with VIM-siRNA (2) and 6-fold (p=0.0004) with VIM-siRNA (3) (Fig 6 B).
Immunohistochemical (IHC) analysis of STIP1 and ALDH1A1 in pancreatic tissue
IHC analysis was performed on pancreatic cancer (PC) tissue (n=5) and corresponding normal
pancreas (NP) tissue specimens (n=5). IHC was used to validate the expression patterns of two
proteins, STIP1 and ALDH1A1. In all cases STIP1 exhibited strong cytoplasmic staining in 5/5
PC specimens, concentrating strongest in areas of perineural invasion and necrotic cells in the
epithelium (Fig A-C). However, STIP1 expression was also observed in the normal ductal and
acinar cells of the exocrine pancreas (Fig 7 D). STIP1 also stained surrounding duodenum,
indicating that STIP1 may not be specific to the pancreas, but may have potential as a target for
invasive cancer. Overall, increased STIP1 expression was observed in the tumour compared to
normal tissues (Fig 7 A-D). Strong ALDH1A1 expression was observed in 2/5 PC (Fig 7 E). This
may be associated with differentiation status, as strong ALDH1A1 expression was exclusive to
well differentiated tumours (Table 1). Three moderate-poorly differentiated pancreatic cancer
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samples exhibited lower levels (<10%) of ALDH1A1 (Fig 7 F-G). ALDH1A1 staining was also
observed in normal pancreas (Fig 7 H), including islet cells.
Discussion
In this study, clonal sub-populations of the human pancreatic cancer cell line, MiaPaCa-2 were
established and their invasion status assessed. Pancreatic cancer is characterised by early invasion
and metastasis. As the invasive and metastatic cascade involves the interaction, attachment and
degradation of the basement membrane in vivo, we allowed the cells grow on matrigel for 24
hours prior to proteomic analysis, to mimic the cells contact with the basement membrane. In this
study, sixty proteins identified as differentially expressed between Clone #3 and Clone #8 by 2D
DIGE followed by MALDI-TOF MS. Bio-informatic profiling of the proteins identified was
performed using GO (gene ontology). The GO STAT profiling of the differentially abundant
proteins between Clone #3 and Clone #8 provided overall analysis of molecular functional
changes in these cells. GO STAT analysis showed that proteins of higher abundance in this study
are more related to the cytoplasm, ATP and nucleotide binding, while some proteins of lower
abundance were exclusively classified as involved in the mitochondrion, suggesting loss of
special organelle functions.
Three novel proteins, ALDH1A1, STIP1 and VIM were chosen to validate and further investigate
their involvement in pancreatic cancer invasion.
ALDH1A1 was expressed at higher levels in the more invasive, Clone #3. ALDH1A1 is an
enzyme involved in the conversion of aldehydes to their corresponding acids by NAD (P) +
dependent reactions [8]. ALDH1A1 activity in cancer has been found to be responsible for
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resistance to oxazaphosphorines such as cyclophosphamide [9, 10] and is involved in the
irreversible oxidization of retinal to retinoic acid (RA) [11], which has been associated with
invasion and adhesion in pancreatic cancer cell lines [12, 13]. Expression of ALDH1A1 was
shown to be up-regulated in the highly malignant ovarian cancer cell line, TOV-112D compared
to the low malignant TOV-81D [14]. ALDH1A1 expression has been linked to more aggressive
tumours suggesting a possible role in the invasive/drug resistance pathways.
Proteins involved in folding, stress response and degradation were also identified as important in
our model. Molecular chaperones and folding enzymes are responsible for protein folding. Stress-
induced phosphoprotein 1 (STIP1) was + 2.0-fold expressed in the highly invasive Clone #3
compared to Clone #8 (low invasion). STIP1 (Hsp70/Hsp90-organising protein (Hop)) mediates
the association of the molecular chaperones Hsp70 and Hsp90 [15]. Heat shock proteins, Hsp90
and Hsp70 have previously been implicated in pancreatic cancer [16, 17]. Eustace et al. [18]
showed that Hsp90α chaperone-complex interactions are involved in MMP-2 activity and
invasiveness in the fibrosarcoma cell line, HT-1080. STIP1 expression, through survival
pathways and MMP activation, could contribute to invasion in the highly invasive Clone #3
pancreatic cancer cell line, therefore making it a potentially valuable target for pancreatic cancer
therapy. Recently Sun et al. [19] confirmed the over expression of STIP1 (HOP) in hepatocellular
carcinoma (HCC) by 2D fluorescence DIGE proteomic analysis. STIP1 is secreted by and shown
to induce proliferation in glioma tumour cells through MAPK and P13 pathways [20].
VIM is a component of intermediate filaments (IF) of the cytoskeleton and is important in cell
motility and movement, maintaining cell shape, integrity of the cytoplasm and stabilising
cytoskeletal interactions. Proteomic analysis revealed an increased expression of VIM in the
highly invasive Clone #3 compared to the low invasive Clone #8. Reduction of VIM expression
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by siRNA decreased the invasion of Clone #3 revealing a role for VIM in pancreatic cancer cell
invasion. Many studies have shown VIM to be substantially expressed in liver metastases of
pancreatic tumours [21], and expression is associated with increased invasiveness and metastasis
potential for epithelial breast carcinoma [22], hepatocellular carcinoma [23] and cervical
carcinoma [24]. Co-expression of VIM and cytokeratins (CKs) is associated with a more
aggressive and metastatic phenotype in breast cancer [22, 25]; however our data demonstrates
increased expression of VIM with an associated decrease in cytokeratin 18 levels in Clone #3.
Singh et al. [26] found that VIM expression contributed to the invasive phenotype of prostate
cancer cell lines but could function at later stages of the invasive process. The high expression
levels of VIM in our invasive cell line could represent a marker for the epithelial to mesenchymal
transition (EMT), in agreement with previous pancreatic cancer studies [27, 28]. Therefore,
expression of VIM could be a confirmatory marker for EMT to a more aggressive phenotype.
Javle et al. [29] found that EMT correlates with the activation of PI3 kinase and Ras/Erk
pathways, which are known to be involved in invasion. Loss of VIM expression, up-regulation of
adhesion proteins and reduced aggressiveness of in vitro invasion is associated with KRT18
expression [7]. However, conflicting reports have implicated KRT18 expression in
carcinogenesis metastatic hepatocellular carcinoma (HCC) tissue [30] and as a predictive marker
for lymph node metastasis in esophageal squamous cell cancer [31].
Conclusions
In summary, knockdown of STIP1 and VIM by siRNA resulted in decreased invasion and
proliferation (STIP1) in the highly invasive pancreatic cancer cell line, Clone #3. Expression of
STIP1 and ALDH1A1 in pancreatic tissue was investigated using IHC analysis of pancreatic
tumour and normal tissue. This is the first time that STIP1 and ALDH1A1 have been implicated
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in invasion and investigated in pancreatic tissue. Our results showed increased expression of
STIP1 in ductal and highly invasive adenocarcinoma cells in the tumours with weaker positive
staining in normal pancreas ducts and acinar cells. Staining of ALDH1A1 was mainly
concentrated to <10% of tumour cells in 3/5 poorly differentiated PC specimens. ALDH1A1
expression was also observed in the stromal and epithelial cells of the normal pancreas.
The proteomic profiling of pancreatic cancer cell lines with different invasion status from the
same genetic background could help to elucidate the molecular mechanisms of pancreatic cancer
invasion and may represent an in vitro model for pancreatic metastasis. The proteins identified in
this study as involved in pancreatic cancer cell invasion may have potential as novel therapeutic
targets and tumour markers of pancreatic cancer. However, the implication of these unique
proteins identified as potential candidates associated with highly invasive pancreatic cancer needs
to be fully evaluated. A large clinical study including serum samples, tissue and pancreatic juice,
would be required in order to identify these proteins as potentially useful for diagnosis, staging,
prognosis and response to therapy of pancreatic cancer.
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Methods
Cell lines
The human pancreatic cell line MiaPaCa-2 was obtained from the European Collection of Cell
Cultures (ECACC, UK). Clone #3 and Clone #8 were obtained by single cell dilution in this
laboratory. Briefly the parental cell line was diluted to a concentration of 3 cells/ml and 100 µl
plated onto each well of a 96-well plate. After 24 hours each well was studied for single cells,
and allowed to grow into colonies. The colonies were then screened by invasion assay to assess
their invasive abilities. Cells were maintained in a humidified atmosphere containing 5 % CO2 at
37 oC in DMEM supplemented with 5 % FCS (Sigma-Aldrich). Antibiotics were not used in the
growth media. All cell lines were free from Mycoplasma as tested with the indirect Hoechst
staining method.
Preincubation of cells with matrigel coated flasks
Matrigel (Sigma-Aldrich, UK) was coated onto flasks (1 ml/25 cm2) at a concentration of 1
mg/ml. The coated flasks were then placed at 4 oC overnight. The flasks were placed into an
incubator at 37 oC for approximately 2 hrs to allow the matrigel polymerise. The excess media in
the flasks was then removed and fresh complete media containing the cell suspension was added.
Cells attached to the matrigel on the bottom of the flask and after 24 hrs were removed with 0.5
ml/T25 cm2 dispase (BD Biosciences). Dispase is a bacillus derived neutral metaloprotease that
recovers cells cultured on matrigel.
Invasion assays
Invasion assays were performed as previously described [32]. 100 µl of matrigel (1 mg/ml) was
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placed into each invasion insert (Falcon) (8.0 µm pore size) in a 24 well plate (Costar). The
coated inserts were incubated overnight at 4 oC. Matrigel was allowed polymerize at 37 oC for 1
hr, then washed with serum-free DMEM. 100 µl of fresh DMEM containing 5% serum was
added to the wells and 1x105/100 µl cells were seeded onto the insert. 500 µl of fresh DMEM
with 5% serum was added to the well. After 24 hour incubation, the inside of the insert was
wiped with a wet cotton swab. The under surface was gently rinsed with PBS and stained with
0.25% crystal violet for 10 minutes, rinsed again with sterile water and allowed to dry. To
determine total number of invading cells, the inserts were then viewed under the microscope and
the number of cells per field in 10 random fields, were counted at 200× magnification. The
average number of cells per field was then multiplied by a factor of 140 (growth area of
membrane/field area viewed at 200× magnification (calibrated using a microscope graticule)).
The mean values were obtained from a minimum of three individual experiments and were
subjected to t-tests.
Sample preparation and protein labelling
Cells at approximately 80% confluency were washed twice in PBS, twice in sucrose buffer before
lysing in buffer containing 4% w/v CHAPS, 7 M urea, 2 M thiourea, 10 mM Tris-HCL, 5 mM
magnesium acetate pH 8.5, and then homogenized by passing through a 25-gauge needle six
times. Insoluble material was removed by centrifugation at 14000 rpm for 20 min at 10 oC.
Protein concentration was determined using the BCA protein assay kit (Bio-Rad). 50 µg of each
biological repeat lysate was labelled with Cy3 and Cy5 (200 pmol) in the dark for 30 min and
quenched with 50-fold molar excess of free lysine-to-dye. Samples were reverse-labelled in order
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to enable all comparisons and eliminate any dye-labelling bias. Reverse-labelling allows one to
differentiate between sample-dependent differences and rare dye-dependent differences.
Samples were mixed and run on the same gels with an equal amount (50 µg) of Cy2-labeled
standard. Cy2 was used as a standard on all gels to aid image matching and cross-gel statistical
analysis [33].
Protein separation by 2-DE and gel imaging
Immobilised 24 cm linear pH gradient (IPG) strips, pH 3-11, were rehydrated in rehydration
buffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer, 50 mM DTT) overnight,
according to manufactures guidelines. IEF was performed using as IPGphor apparatus (GE
Healthcare) for 40 kV/h at 20 oC with resistance set at 50 mA. Strips were equilibrated for 20 min
in 50 mM Tris-HCL, pH 8.8, 6 M urea, 30% v/v glycerol, 1% w/v SDS containing 65 mM DTT
and the for 20 min in the same buffer containing 240 mM iodoacetamide. Equilibrated IPG strips
were transferred onto 18 x 20 cm 12.5% uniform polyacrylamide gels poured between low
fluorescence glass plates. Strips were overlaid with 0.5% w/v low melting point agarose in
running buffer containing bromophenol blue. Gels were run at 2.5 W/gel for 30 min and then 100
W total at 10 oC. All the images were collected on a Typhoon 9400 Variable Mode Imager (GE
Healthcare). Statistics and quantification of protein expression were carried out in DeCyder
software (GE Healthcare).
Spot digestion and MALDI-TOF analysis
Excision of protein spots, trypsin digestion and protein identification by MS analysis using an
Ettan MALDI-TOF Pro (GE Healthcare) was performed. Preparative gels containing 300 µg of
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protein were fixed in 30% v/v methanol, 7.5% v/v acetic acid overnight and washed in water, and
total protein was detected by post-staining with CBB and Deep purple stain (Molecular Probes)
for 3 hrs at room temperature. Excess dye was removed by washing twice in water, and gels were
imaged using a Typhoon 9400 Variable Mode Imager (GE Healthcare) at the appropriate
excitation and emission wavelengths for the stain. The subsequent gel image was imported into
the BVA module of DeCyder software and was matched to images generated from DIGE
analysis. Spots of interest were selected and confirmed using this software for subsequent picking
using an Ettan Spot Picker. Gel plugs were placed into a presiliconised 1.5 ml plastic tube for
destaining, desalting and washing steps. The remaining liquid above the gel plugs was removed
and sufficient ACN was added in order to cover the gel plugs. Following shrinkage of the gel
plugs, ACN was removed and the protein containing gel pieces were rehydrated for 5 min with a
minimal volume of 100 mM ammonium bicarbonate. An equal volume of ACN was added, and
after 15 min of incubation the solution was removed from the gel plugs and the samples were
dried for 30 min using a vacuum centrifuge. Individual gel pieces were then rehydrated in
digestion buffer (12.5 ng trypsin per µl of 10% ACN, 40 mM ammonium bicarbonate) to cover
the gel pieces. Exhaustive digestion was carried out overnight at 37 oC. After digestion, the
samples were centrifuged at 12000 x g for 10 min using a bench top centrifuge. The supernatant
was carefully removed from each sample and placed into clean plastic tubes. Samples were stored
at -80 oC until analysed by M.S. For spectrometric analysis, mixtures of tryptic peptides from
individual samples were desalted using Millipore C-18 Zip-Tips (Millipore) and eluted onto the
sample plate with the matrix solution (5 mg/ml CHCA in 50% ACN/0.1% TFA v/v). Mass
spectra were recorded using the MALDI-TOF instrument operating in the positive reflectron
mode at the following parameters: accelerating voltage 20 kV; and pulsed extraction; on (focus
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mass 2500). Internal calibration was performed using anti-analysis peaks at m/z 842.50, m/z
2211.104 and external calibration was performed using Pep4 mix. The mass spectra were
analysed using MALDI evaluation software (GE Healthcare), and protein identification was
achieved with the PMF Pro-Found search engine. An expectation value of < 0.002 was used for
all reported identifications, which indicates a 0.2% chance the identification is random.
Immunoblotting
Whole protein was extracted from cell lysates using 1x lysis buffer (50 mM Tris-Cl, 150 mM
NaCl, and 0.5% NP-40). Lysates were centrifuged for 10 min at 14,000 rpm at 4o C. Protein
concentrations were determined using the Bio-Rad protein assay (Bio-Rad). 35 µg of protein was
separated by 7.5% and 15% SDS-PAGE under reducing conditions. Proteins were transferred to
nitrocellulose membrane, efficiency and equal loading of protein was visualised by Ponceau S
staining. Membranes were blocked at 4 oC overnight in TBS (25mM Tris-HCl, pH 7.4, 150mM
NaCl, 2.7mM KCl) containing 5% (w/v) lowfat milk powder. Membranes were probed with
monoclonal antibodies, anti-aldehyde dehydrogenase (Abcam), anti-stress-induced
phosphoprotein 1 (Santa Cruz), anti-cytokeratin 18 (Santa Cruz Biotechnology), anti-vimentin
(Sigma), anti-GAPDH (Applied Biosystems). Secondary antibodies, anti-mouse, anti-rabbit and
anti-goat were obtained from Sigma. Protein bands were detected with Luminol reagent (Santa
Cruz Biotechnology).
siRNA transient transfections
Three pre-designed STIP1 and VIM-siRNAs (Ambion) were chosen and transfected into cells.
For each set of siRNA transfections carried out, a control (non-transfected) and a scrambled
(SCR) siRNA transfected control were used. siRNA experiments were set up using 2 µl NeoFx to
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transfect 30 nM siRNA in a cell density of 3x105 per well of a 6-well plate. Transfection medium
was removed after 24 hours and replaced with fresh growth medium. The transfected cells were
collected for immunoblot and assayed for changes in invasion capacity at 48 hours using the in
vitro invasion assay (as previously described).
IHC analysis
Patients
The patient group consisted of 5 consenting patients diagnosed with primary tumours of the
pancreas. All patients were treated at St. Vincent’s University Hospital (SVUH), Dublin in 2005.
IHC studies on tumour-free pancreatic tissue were performed using corresponding non-cancerous
tissue. Pathological material was examined on each case by SK. Formalin-fixed paraffin-
embedded pancreatic tumour tissue and corresponding normal pancreas was available for all
patients. Representative 4-µm sections of tissue block were cut using a microtome, mounted onto
poly-l-lysine coated slides and dried overnight at 37 oC. Slides were stored at room temperature
until required.
Immunohistochemistry
Briefly the slides were immunohistochemically stained using primary antibodies specific for
ALDH1A1 and STIP1 from Abcam. The staining procedure includes an antigen retrieval step
consisting of 20-minute incubation in pH 9.0 buffer (TARGET Retrieval, Dako) in a 95°C water
bath followed by cooling to room temperature. Staining was performed using an automated
staining apparatus for IHC (Autostainer, Dako) according to the manufacturer’s guidelines. The
slides were counterstained with haematoxylin.
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Figure legends
Figure 1 Graph displays the total number of cells invading after 24 hr incubation on matrigel of
Clone #8, MiaPaCa-2 and Clone #3. Experiments performed in triplicate.
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Figure 2 Representative 2D DIGE gel image of Cy2-labelled pool of Clone #3 and Clone #8 cell
lysate samples. Differentially expressed proteins that have been successfully identified by
MALDI-TOF MS (p ≤ 0.05, protein fold ≥ 1.2) are represented on the gel using DeCyder
software. Proteins are labelled numerically for visual clarity and are outlined in Table 1
Figure 3 Term-ranking Gene Ontology categories. Representation of the 10 top-ranked
functional categories, using GO terms that are enriched in all significantly differentially
expressed proteins between Clone #3 versus Clone #8.
Figure 4 Differentially expressed proteins, A. ALDH1A1, B. VIM, C. STIP1, D. KRT18 and E.
GAPDH in Clone #3 versus Clone #8 confirmed by (i) 3D spot image, (ii) PEM spot and (iii)
immunoblot.
Figure 5 A. Immunoblot of STIP1 silencing in Clone #3 cells untreated control, scrambled
control, STIP1-siRNA (1), STIP1-siRNA (2) and STIP1-siRNA (3) (upper) and α-tubulin as
loading control (lower). B. Total number of invading cells after siRNA transfection in Clone #3
untreated control, scrambled control, STIP1-siRNA (1), STIP1-siRNA (2) and STIP1-siRNA (3).
Results are displayed as the total number of invading cells, determined by counting the number of
cells per field in 10 random fields, at 200× magnification. The average number of cells per field
was then multiplied by a factor of 140 (growth area of membrane/field area viewed at 200×
magnification (calibrated using a microscope graticule)). Experiments performed in triplicate.
Total mean number of cells invading at 200x magnification (n = 3). C. Proliferation assays of
Clone #3 untreated control, scrambled control, STIP1-siRNA (1), STIP1-siRNA (2) and STIP1-
siRNA (3). Results displayed as percentage survival relative to untreated control. Student’s t-test;
p ≤ 0.05*, 0.01**, 0.005*** (n=3).
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Figure 6 A. Immunoblot of VIM knockdown in Clone #3 untreated control, scrambled control,
VIM-siRNA (1), VIM-siRNA (2) and VIM-siRNA (3) (upper) and α-tubulin as loading control
(lower). B. Invasion assay of Clone #3 cells after siRNA silencing of VIM. The total number of
invading cells was determined by counting the number of cells per field in 10 random fields, at
200× magnification. The average number of cells per field was then multiplied by a factor of 140
(growth area of membrane/field area viewed at 200× magnification (calibrated using a
microscope graticule)). Experiments performed in triplicate. Statistics; * ≤ 0.05, ** ≤ 0.01, *** ≤
0.005.
Figure 7 IHC detection of STIP1 (A-D) and ALDH1A1 (E-H) in pancreatic cancer and normal
pancreas tissues. (A) Strong STIP1 cytoplasmic staining in PC tumour ducts. (B-C) Strong
STIP1 expression in poorly differentiated PC tumours. (D) Moderate staining of normal pancreas
ducts and acinar cells. (E) ALDH1A1 highly expressed in well differentiated PC tumour. (F-G)
Weak ALDH1A1 staining observed in <10% of poorly differentiated PC tumours. (H) Positive
staining in epithelial cells of normal pancreas. Original magnification 200×.
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Table 1: Type of pancreatic cancer included in the study
Sex Age Tumour Type Tumour Grade Lymph node
status
PC-01 M 48 Adenocarcinoma, ductal Moderately differentiated + ve
PC-02 F 43 Adenocarcinoma Well differentiated - ve
PC-03 F 67 Adenocarcinoma Well differentiated -ve
PC-04 M 36 Adenocarcinoma Poorly differentiated + ve
PC-05 M 67 Squamous cell Poorly differentiated No nodes
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